Blood Eosinophilia is an on-Treatment Biomarker in Patients with Solid Tumors Undergoing Dendritic Cell Vaccination with Autologous Tumor-RNA.

Pharmaceutics · 2020 · PMC7150785 · PMID 32121531

Europe PMC DOI

hedged sentences

0.0300

closest p · 0.6× alpha

0.0300

boldest claim

The sentences

a clear trendp = 0.03actually significant

DC-vaccinated patients who developed eosinophilia of 20% or more at any point during the course of vaccinations showed a clear trend toward longer survival ( p = 0.03; Figure 2 ).

also in 19,460 other papers

showed a trendno p-value reported

While prevaccination eosinophil levels were not associated with survival, patients with blood eosinophilia at any point after initiation of DC-based immunotherapy showed a trend towards longer survival.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.